S&P 500   4,145.19
DOW   32,803.47
QQQ   321.75
Buffett's firm reports $44B loss but its businesses thrive
pixel
Musk says Twitter deal could move ahead with 'bot' info
Senate parliamentarian OKs most of Dems' drug price controls
Dems' climate, energy, tax bill clears initial Senate hurdle
pixel
Senate rules referee weakens Dem drug plan in economic bill
Demand for grocery delivery cools as food costs rise
Venezuela, Colombia border areas hopeful as reopening looms
pixel
S&P 500   4,145.19
DOW   32,803.47
QQQ   321.75
Buffett's firm reports $44B loss but its businesses thrive
pixel
Musk says Twitter deal could move ahead with 'bot' info
Senate parliamentarian OKs most of Dems' drug price controls
Dems' climate, energy, tax bill clears initial Senate hurdle
pixel
Senate rules referee weakens Dem drug plan in economic bill
Demand for grocery delivery cools as food costs rise
Venezuela, Colombia border areas hopeful as reopening looms
pixel
S&P 500   4,145.19
DOW   32,803.47
QQQ   321.75
Buffett's firm reports $44B loss but its businesses thrive
pixel
Musk says Twitter deal could move ahead with 'bot' info
Senate parliamentarian OKs most of Dems' drug price controls
Dems' climate, energy, tax bill clears initial Senate hurdle
pixel
Senate rules referee weakens Dem drug plan in economic bill
Demand for grocery delivery cools as food costs rise
Venezuela, Colombia border areas hopeful as reopening looms
pixel
S&P 500   4,145.19
DOW   32,803.47
QQQ   321.75
Buffett's firm reports $44B loss but its businesses thrive
pixel
Musk says Twitter deal could move ahead with 'bot' info
Senate parliamentarian OKs most of Dems' drug price controls
Dems' climate, energy, tax bill clears initial Senate hurdle
pixel
Senate rules referee weakens Dem drug plan in economic bill
Demand for grocery delivery cools as food costs rise
Venezuela, Colombia border areas hopeful as reopening looms
pixel
NASDAQ:LJPC

La Jolla Pharmaceutical (LJPC) Stock Forecast, Price & News

$6.20
0.00 (0.00%)
(As of 08/5/2022 12:00 AM ET)
Add
Compare
Today's Range
$6.20
$6.21
50-Day Range
$3.12
$6.22
52-Week Range
$3.07
$6.22
Volume
73,611 shs
Average Volume
544,103 shs
Market Capitalization
$154.57 million
P/E Ratio
41.33
Dividend Yield
N/A
Price Target
N/A

La Jolla Pharmaceutical MarketRank™ Forecast

Analyst Rating
N/A
Upside/​Downside
N/A
Short Interest
Healthy
0.81% of Float Sold Short
Dividend Strength
N/A
Sustainability
-2.77
Upright™ Environmental Score
News Sentiment
0.30mentions of La Jolla Pharmaceutical in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
475.00%
From $0.04 to $0.23 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.86 out of 5 stars

Medical Sector

44th out of 1,283 stocks

Biological Products, Except Diagnostic Industry

4th out of 197 stocks

La Jolla Pharmaceutical logo

About La Jolla Pharmaceutical (NASDAQ:LJPC) Stock

La Jolla Pharmaceutical Company engages in the development and commercialization of therapies that improve outcomes in patients suffering from life-threatening diseases. The company offers GIAPREZA, a vasoconstrictor indicated to increase blood pressure in adults with septic or other distributive shock; and XERAVA, a tetracycline class antibacterial indicated for the treatment of complicated intra-abdominal infections in patients 18 years of age and older. It offers GIAPREZA and XERAVA to hospitals and other healthcare organizations in the United States. Its product candidates that are in early stage clinical or preclinical development include TP-6076, an IV formulation of a fully synthetic fluorocycline derivative for the treatment of certain multidrug-resistant gram-negative bacteria; TP-271, an IV and oral formulation of a fully synthetic fluorocycline for the treatment of respiratory disease caused by bacterial biothreat and antibiotic-resistant public health pathogens, as well as bacterial pathogens associated with community-acquired bacterial pneumonia; and TP-2846, an IV formulation of a tetracycline for the treatment of acute myeloid leukemia. The company has license agreement with Everest Medicines Limited to develop and commercialize XERAVA; and PAION AG to commercialize GIAPREZA and XERAVA. La Jolla Pharmaceutical Company was incorporated in 1989 and is based in Waltham, Massachusetts.

Analyst Upgrades and Downgrades

A number of brokerages recently commented on LJPC. TheStreet upgraded shares of La Jolla Pharmaceutical from a "d+" rating to a "c-" rating in a research note on Friday, July 29th. StockNews.com assumed coverage on shares of La Jolla Pharmaceutical in a report on Friday, July 15th. They issued a "hold" rating for the company.

La Jolla Pharmaceutical Price Performance

NASDAQ:LJPC remained flat at $6.20 during trading on Friday. 73,611 shares of the company's stock were exchanged, compared to its average volume of 544,103. The stock has a market cap of $154.57 million, a price-to-earnings ratio of 41.33 and a beta of 2.39. La Jolla Pharmaceutical has a 52-week low of $3.07 and a 52-week high of $6.22. The company has a 50 day moving average of $4.57 and a 200 day moving average of $4.33.

La Jolla Pharmaceutical (NASDAQ:LJPC - Get Rating) last issued its quarterly earnings results on Monday, May 16th. The biopharmaceutical company reported ($0.15) earnings per share for the quarter, missing analysts' consensus estimates of $0.01 by ($0.16). La Jolla Pharmaceutical had a negative return on equity of 7.27% and a net margin of 10.08%. The firm had revenue of $10.43 million for the quarter, compared to the consensus estimate of $13.10 million. As a group, research analysts anticipate that La Jolla Pharmaceutical will post 0.04 earnings per share for the current fiscal year.

Receive LJPC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for La Jolla Pharmaceutical and its competitors with MarketBeat's FREE daily newsletter.

LJPC Stock News Headlines

La Jolla Pharmaceutical Co Stock News
Dow Dips Around 90 Points; La Jolla Pharmaceutical Shares Surge
3 Biotech Stocks Under $5 to Buy Now
See More Headlines

Receive LJPC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for La Jolla Pharmaceutical and its competitors with MarketBeat's FREE daily newsletter.

LJPC Company Calendar

Last Earnings
5/16/2022
Today
8/07/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:LJPC
Employees
61
Year Founded
N/A

Profitability

Net Income
$19.66 million
Pretax Margin
10.15%

Debt

Sales & Book Value

Annual Sales
$75.72 million
Cash Flow
$0.78 per share
Book Value
($2.57) per share

Miscellaneous

Free Float
15,878,000
Market Cap
$154.57 million
Optionable
Optionable
Beta
2.39

Key Executives

  • Mr. Larry G. Edwards (Age 50)
    Pres, CEO & Director
    Comp: $858.87k
  • Mr. Michael S. Hearne (Age 59)
    CFO & Sec.
    Comp: $207.38k
  • Ms. Paula Rusu
    VP of Operations
  • Ms. Sandra Vedrick
    Sr. Director of Investor Relations & HR
  • Mr. Luke Seikkula (Age 58)
    Sr. VP of Pharmaceutical Operations
  • Dr. Lakhmir S. Chawla M.D. (Age 51)
    Consultant
  • Mr. Stewart M. Kroll (Age 63)
    Chief Devel. Officer
  • Mr. Mark D. Williams
    Sr. VP of Medical Affairs
  • Mr. Tony N. Hodges FACP
    M.D., Chief Medical Officer













LJPC Stock - Frequently Asked Questions

How has La Jolla Pharmaceutical's stock price performed in 2022?

La Jolla Pharmaceutical's stock was trading at $4.65 on January 1st, 2022. Since then, LJPC shares have increased by 33.3% and is now trading at $6.20.
View the best growth stocks for 2022 here
.

Are investors shorting La Jolla Pharmaceutical?

La Jolla Pharmaceutical saw a drop in short interest in the month of July. As of July 15th, there was short interest totaling 202,500 shares, a drop of 62.7% from the June 30th total of 543,500 shares. Based on an average trading volume of 196,400 shares, the short-interest ratio is currently 1.0 days. Approximately 0.8% of the shares of the stock are sold short.
View La Jolla Pharmaceutical's Short Interest
.

How were La Jolla Pharmaceutical's earnings last quarter?

La Jolla Pharmaceutical (NASDAQ:LJPC) released its quarterly earnings results on Monday, May, 16th. The biopharmaceutical company reported ($0.15) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.01 by $0.16. The biopharmaceutical company had revenue of $10.43 million for the quarter, compared to analyst estimates of $13.10 million. La Jolla Pharmaceutical had a negative trailing twelve-month return on equity of 7.27% and a net margin of 10.08%.

What is George F. Tidmarsh's approval rating as La Jolla Pharmaceutical's CEO?

8 employees have rated La Jolla Pharmaceutical CEO George F. Tidmarsh on Glassdoor.com. George F. Tidmarsh has an approval rating of 49% among La Jolla Pharmaceutical's employees. This puts George F. Tidmarsh in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of La Jolla Pharmaceutical own?

Based on aggregate information from My MarketBeat watchlists, some companies that other La Jolla Pharmaceutical investors own include BioCryst Pharmaceuticals (BCRX), Intercept Pharmaceuticals (ICPT), Exelixis (EXEL), Neurocrine Biosciences (NBIX), Advanced Micro Devices (AMD), El Pollo Loco (LOCO), Sarepta Therapeutics (SRPT), Inovio Pharmaceuticals (INO), NVIDIA (NVDA) and XOMA (XOMA).

What is La Jolla Pharmaceutical's stock symbol?

La Jolla Pharmaceutical trades on the NASDAQ under the ticker symbol "LJPC."

Who are La Jolla Pharmaceutical's major shareholders?

La Jolla Pharmaceutical's stock is owned by a number of retail and institutional investors. Top institutional investors include HealthInvest Partners AB (4.95%), Hollencrest Capital Management (0.31%), OLD National Bancorp IN (0.16%) and Ritholtz Wealth Management (0.07%). Company insiders that own La Jolla Pharmaceutical stock include Darryl Wellinghoff, David A Ramsay and Kevin C Tang.
View institutional ownership trends for La Jolla Pharmaceutical
.

How do I buy shares of La Jolla Pharmaceutical?

Shares of LJPC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is La Jolla Pharmaceutical's stock price today?

One share of LJPC stock can currently be purchased for approximately $6.20.

How much money does La Jolla Pharmaceutical make?

La Jolla Pharmaceutical (NASDAQ:LJPC) has a market capitalization of $154.57 million and generates $75.72 million in revenue each year. The biopharmaceutical company earns $19.66 million in net income (profit) each year or $0.15 on an earnings per share basis.

How many employees does La Jolla Pharmaceutical have?

La Jolla Pharmaceutical employs 61 workers across the globe.

How can I contact La Jolla Pharmaceutical?

La Jolla Pharmaceutical's mailing address is 4550 TOWNE CENTRE COURT, SAN DIEGO CA, 92121. The official website for La Jolla Pharmaceutical is www.lajollapharmaceutical.com. The biopharmaceutical company can be reached via phone at (617) 715-3600, via email at info@ljpc.com, or via fax at 858-626-2851.

This page (NASDAQ:LJPC) was last updated on 8/7/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.